Abstracts tagged "pain"

Abstract Number: 1230 • 2012 ACR/ARHP Annual Meeting
The Role of Sleep Problems in Conditioned Pain Modulation in Rheumatoid Arthritis
Yvonne C. Lee¹, Bing Lu², Robert R. Edwards³, Ajay Wasan⁴, Nicholas Nassikas⁵, Daniel J. Clauw⁶, Daniel H. Solomon⁷ and Elizabeth W. Karlson⁸, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Anesthesiology, Brigham & Womens Hospital, Chestnut Hill, MA, ⁴Anesthesiology, Brigham and Women's Hospital, Chestnut Hill, MA, ⁵Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁶Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ⁷Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁸Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Among rheumatoid arthritis (RA) patients, pain may exist out of proportion to peripheral inflammation. This observation suggests that central nervous system pain amplification…
Abstract Number: 954 • 2012 ACR/ARHP Annual Meeting
Diagnosis of Secondary Fibromyalgia in an Established Rheumatoid Arthritis Cohort
Yvonne C. Lee¹, Christine K. Iannaccone¹, Michelle A. Frits¹, M. Weinblatt² and Nancy A. Shadick³, ¹Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: The prevalence of fibromyalgia (FM) is 7-10 times higher among rheumatoid arthritis (RA) patients than the general population. However, the diagnosis of FM in…
Abstract Number: 960 • 2012 ACR/ARHP Annual Meeting
Cyclobenzaprine (CBP) and Its Major Metabolite Norcyclobenzaprine (nCBP) Are Potent Antagonists of Human Serotonin Receptor 2a (5HT2a), Histamine Receptor H-1 and á-Adrenergic Receptors: Mechanistic and Safety Implications for Treating Fibromyalgia Syndrome by Improving Sleep Quality
Bruce Daugherty, Leland Gershell and Seth Lederman, Research and Development, Tonix Pharmaceuticals, Inc., New York, NY
Background/Purpose: Bedtime cyclobenzaprine (CBP) improves fibromyalgia symptoms (pain, fatigue, tenderness, and mood) and improves sleep quality (decreases Cyclic Alternating Pattern Type A2 + A3) (1).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].